• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
  • approach
  • pipeline
  • news & insights
    • presentations
    • press releases
    • references (PRL-02)
    • references (CGS-200-5)
  • careers
  • contact
  • Menu
  • newsworthy &
    insightful

    Stay updated and informed about all things Propella.

Presentation: Abstract 337037: A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)

/in presentations /by george

Propella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting on June 4, 2021.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-06-07 20:44:282021-09-09 15:19:45Presentation: Abstract 337037: A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)

Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer

/in press releases /by george

Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-05-19 19:12:482022-01-04 09:10:35Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer

Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

/in press releases /by george

Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-02-23 16:22:522021-09-09 15:19:57Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

Presentation: Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model (citation and abstract are found at https://meetinglibrary.asco.org/record/194919/abstract)

/in presentations /by george

Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium on February 11, 2021.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-02-22 11:33:212021-09-09 15:20:05Presentation: Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model (citation and abstract are found at https://meetinglibrary.asco.org/record/194919/abstract)

Presentation: Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target

/in presentations /by george

Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-02-20 00:37:592021-09-09 15:20:14Presentation: Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target

Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)

/in presentations /by george

Propella Therapeutics, Inc. presented the results of its recently completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-01-15 01:30:302021-09-09 15:25:28Presentation: A Phase 2 Double-Blind Clinical Trial (VZU00025) to Examine the Tolerability, Safety and Effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on Osteoarthritis Knee Pain (OAKP) (Presented at the 14th Annual Pain Therapeutics Summit on September 21-22, 2020)
Page 2 of 6‹1234›»

categories

  • presentations
  • press releases
  • references (CGS-200-5)
  • references (PRL-02)
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • careers
  • contact
© 2020-2022 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top